What is the metabolic theory of cancer?
Most of us have been taught to think of cancer as, fundamentally, a genetic disease — a story of mutations, of DNA going wrong, of cells that have lost their instruction manual. It’s a compelling narrative, and not an inaccurate one. But it is incomplete. There is a parallel body of research, growing in rigour and influence over the past two decades, that points to something the genetic model cannot fully explain: why cancer cells behave so differently from healthy ones even before they accumulate the full complement of mutations thought to drive malignancy, and why changing the metabolic environment of the body appears, in certain contexts, to matter.
This is the first post in a ten-part series exploring the metabolic theory of cancer — what the evidence shows, what it does not, and what it might mean for how we approach our health. We begin at the beginning, with a biochemist named Otto Warburg, and a discovery that sat at the edges of mainstream oncology for nearly a century before finding its way back to the centre.
The science in brief: Otto Warburg and the aerobic glycolysis paradox
In 1924, Otto Warburg — a German biochemist who would go on to win the Nobel Prize in Physiology or Medicine in 1931 — made an observation that would prove difficult to explain for decades. He noticed that cancer cells consume glucose at a dramatically higher rate than healthy cells, and that they ferment it into lactic acid even in the presence of abundant oxygen. This is peculiar because fermentation is a far less efficient way of generating energy than oxidative phosphorylation, the process healthy cells prefer when oxygen is available. Warburg called this phenomenon aerobic glycolysis; it has since become known as the Warburg effect.
The question it raises is a logical one: why would a rapidly dividing cell — one with enormous energy demands — choose a metabolic pathway that produces far less ATP per molecule of glucose? Warburg believed the answer lay in mitochondrial dysfunction: that cancer cells had damaged or dysfunctional mitochondria, and were reverting to a more primitive metabolic strategy as a consequence. His hypothesis, which he articulated throughout the 1950s, was that the primary cause of cancer was a disruption to cellular respiration.
The scientific community largely set this idea aside as genetics came to dominate oncology in the latter decades of the twentieth century. But the Warburg effect itself — the observation that tumour cells preferentially ferment glucose regardless of oxygen availability — was never in dispute, and it became the basis of one of the most widely used tools in cancer diagnostics: the PET scan, which works precisely because cancer cells take up radiolabelled glucose so avidly.
In the past two decades, interest in the metabolic underpinnings of cancer has been substantially renewed. A 2012 review by Upadhyay and colleagues, published in Pharmacology & Therapeutics, provides a detailed mechanistic account of the Warburg effect and its therapeutic implications. The authors describe how aerobic glycolysis in tumour cells is not simply a passive consequence of mitochondrial damage, but appears to be actively regulated — driven in part by oncogenes such as c-Myc and signalling pathways including PI3K/Akt/mTOR, which are frequently dysregulated in cancer. A parallel review, also from 2012 and published in Acta Biomedica, argues that the metabolic reprogramming of cancer cells is not merely incidental to malignancy but may be a foundational mechanism driving it. Both are mechanistic reviews drawing on cellular and biochemical evidence; they do not, in isolation, establish what this means for human cancer prevention or treatment. It is important to be clear about that.
Why the Warburg effect matters — and what it suggests
The significance of the Warburg effect extends beyond biochemical curiosity. If cancer cells are metabolically distinct from healthy cells — if they rely disproportionately on glucose fermentation, and if this reliance is driven partly by systemic metabolic signals rather than purely by genetic mutations — then it raises a genuine question: does the metabolic environment of the body influence how cancer develops, progresses, or responds to treatment?
The answer, based on the current body of human evidence, is: possibly, and in some contexts, meaningfully. But the evidence is at different stages of maturity depending on the specific intervention and cancer type, and we will work through it carefully across this series.
What we can say with reasonable confidence is that chronic elevations in blood glucose and insulin are associated with increased cancer risk across multiple cancer types — a finding supported by large prospective cohort studies. That exercise appears to improve survival outcomes in certain cancer populations, as established in at least one recent phase 3 randomised controlled trial. That dietary quality appears to influence cancer prognosis. And that more experimental approaches — including ketogenic diets and fasting protocols designed to reduce glucose availability to tumour cells — have shown early feasibility in small trials, though the evidence base is preliminary.
Each of these areas will be the subject of its own post in this series. The point here is not to claim that metabolic interventions can treat cancer — they cannot be described in those terms on current evidence — but to explain why the metabolic theory provides a coherent biological framework for understanding why lifestyle choices might have relevance to cancer risk and cancer outcomes.
What this means in practice
Understanding the Warburg effect does not, by itself, tell you what to eat for breakfast. But it does give you a mechanistic basis for taking the lifestyle evidence seriously, rather than treating it as vague wellness advice. Here are three grounded starting points.
Pay attention to blood glucose regulation. Cancer cells consume glucose at high rates, and chronically elevated blood glucose — driven by diet, sedentary behaviour, poor sleep, and chronic stress — is independently associated with increased cancer risk. This is not a reason to fear fruit or obsess over carbohydrates, but it is a reason to take seriously the patterns of eating and movement that support stable blood glucose across the day. We’ll look at the specific evidence in post two.
Consider the role of insulin. Insulin is a growth-promoting hormone, and insulin resistance — the state in which cells respond poorly to insulin’s signals — is associated with elevated circulating insulin levels. The connection between insulin resistance and cancer risk is an active area of research, and one we’ll explore in depth. Managing insulin sensitivity through diet, exercise, and sleep quality is one of the most evidence-supported things you can do for your metabolic health generally.
Don’t underestimate the relevance of mitochondrial health. The Warburg effect is, at its core, about how cells generate energy. Mitochondria are central to that story, and there is a growing body of evidence — across multiple chronic disease areas, not only cancer — that supporting mitochondrial function through adequate sleep, consistent physical activity, and avoidance of significant nutritional deficiencies is meaningful. We don’t yet have definitive human trial data showing that improving mitochondrial function reduces cancer incidence, but the mechanistic case is coherent and the lifestyle interventions involved are low-risk.
What the evidence does not yet show
The metabolic theory of cancer is not a settled science. Warburg’s original hypothesis — that mitochondrial dysfunction is the primary cause of cancer — is not accepted in its original form by the mainstream scientific community, which views cancer as a multifactorial disease with genetic, epigenetic, metabolic, and environmental drivers interacting in complex ways. The question of whether metabolic reprogramming in tumour cells is a cause or a consequence of malignancy remains contested and likely varies between cancer types.
Importantly, no human trial has yet demonstrated that a metabolic dietary intervention — ketogenic diet, fasting, or glucose restriction — can prevent cancer in healthy individuals or treat established cancer as a standalone intervention. The trials that exist in this area are small, involve specific cancer types (primarily glioma), and have studied feasibility and safety rather than survival outcomes. We will cover these honestly when we reach post five.
The evidence for lifestyle factors — exercise, dietary quality, body composition — is on considerably firmer ground, particularly for cancer survivors, and we will spend more time there. But even that evidence must be interpreted carefully: association is not causation, and we’ll be precise about what the study designs can and cannot establish.
The bottom line
The Warburg effect is real, well-documented, and clinically useful — it underpins cancer imaging. The broader metabolic theory of cancer — the idea that the metabolic environment of the body is a meaningful factor in cancer risk and progression — is scientifically coherent and supported by a growing body of human evidence, even if it remains an active area of research rather than settled medicine. Over the next nine posts, we’ll look carefully at what the trial data actually shows, where the evidence is strong, where it is preliminary, and what practical steps sit within reach for anyone motivated to engage with this emerging science.
Scientific references
- Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect: insights from the past decade. Pharmacology & Therapeutics, 2012. DOI: 10.1016/j.pharmthera.2012.11.003
- Towards a metabolic therapy of cancer. Acta Biomedica, 2012. PMID: 23762991
Medical disclaimer
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
